Cite
Kang M, Jeong CW, Kwak C, et al. Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget. 2017;8(35):59690-59697doi: 10.18632/oncotarget.17741.
Kang, M., Jeong, C. W., Kwak, C., Ku, J. H., & Kim, H. H. (2017). Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget, 8(35), 59690-59697. https://doi.org/10.18632/oncotarget.17741
Kang, Minyong, et al. "Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials." Oncotarget vol. 8,35 (2017): 59690-59697. doi: https://doi.org/10.18632/oncotarget.17741
Kang M, Jeong CW, Kwak C, Ku JH, Kim HH. Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget. 2017 May 10;8(35):59690-59697. doi: 10.18632/oncotarget.17741. eCollection 2017 Aug 29. PMID: 28938672; PMCID: PMC5601768.
Copy
Download .nbib